A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC). The study will also see whether taking 1 large dose of L-756423/IDV once a day is as safe and effective as taking 2 smaller doses twice a day.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Indinavir; Lamivudine; Stavudine

Criteria

Inclusion Criteria

You may be eligible for this trial if you:

• Have HIV infection.

• Have levels of CD4 cells of 100 cells/mm3 or greater.

• Have a viral load of 10,000 copies/ml or greater.

• Are 18 years of age or older.

Exclusion Criteria

You may not be eligible for this trial if you:

• Have ever taken anti-HIV drugs.